StreetInsider.com News Articles

Form 4 Allarity Therapeutics, For: Jan 22 Filed by: Graff Jeremy R.

Fri, 09 Oct 2026 17:13:00 -0400

si-local-file:///var/storage/secattach/20261009/27172279.html

Form 8-K Allarity Therapeutics, For: Sep 30

Thu, 01 Oct 2026 08:00:00 -0400

si-local-file:///var/storage/secattach/20261001/27131824.html

Allarity updates DRP technology with new patents and lab certification

Wed, 30 Sep 2026 09:00:56 -0400

Allarity Therapeutics, Inc. (NASDAQ: ALLR) provided an update on its Drug Response Predictor (DRP®) technology, reporting recent patent awards and the CLIA certification of its in-house laboratory as part of its clinical development strategy for stenoparib, according to a company statement dated September 30, 2026.

The stenoparib-DRP® test is based on a 414-gene expression signature that includes genes associated with WNT pathway activity. At the American Association for Cancer Research (AACR) 2026 conference, Allarity presented an exploratory analysis showing that higher pretreatment DRP scores were associated with longer overall survival in a prior Phase 2 cohort of patients with advanced ovarian

Allarity Provides Update on Key Recent Advances Solidifying Drug Response Predictor® to Drive Stenoparib’s Clinical Development

Wed, 30 Sep 2026 09:00:00 -0400

- Recently awarded patents have solidified Allarity’s strategy to leverage DRP to ensure the commercial exclusivity of stenoparib

TARPON SPRINGS, Fla., September 30, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor—
today provided an update on recent advances in its proprietary Drug Response Predictor (DRP®) technology, patent portfolio and in-house laboratory capabilities that strengthen its ability to drive stenoparib’s clinical development while expanding external partnership opportunities.

Allarity Therapeutics was established on its

Allarity Provides Update on Key Recent Advances Solidifying Drug Response Predictor® to Drive Stenoparib’s Clinical Development

Wed, 30 Sep 2026 09:00:00 -0400

- Recently awarded patents have solidified Allarity’s strategy to leverage DRP to ensure the commercial exclusivity of stenoparib

Allarity Therapeutics was established on its

Form 8-K Allarity Therapeutics, For: Sep 28

Tue, 29 Sep 2026 08:01:00 -0400

si-local-file:///var/storage/secattach/20260929/27117766.html

Allarity adds proteomics and cell line research to its laboratory

Mon, 28 Sep 2026 08:01:23 -0400

Allarity Therapeutics, Inc. (NASDAQ: ALLR) announced it has expanded its in-house medical laboratory to include proteomics and cell line research capabilities, according to a company statement.

The additions build on the laboratory's existing transcriptomics research and CLIA clinical testing services. The company said the expanded capabilities are intended to support internal research into the mechanism of action of its lead drug candidate, stenoparib, and to broaden laboratory services available to external partners.

Allarity's laboratory uses an nCounter Pro instrument for transcriptomics research. The company said the platform can now also be applied to proteomics research using the nCounter Human Tumor Signaling Protein

Allarity Therapeutics Expands Laboratory Capabilities to Include Proteomics and Cell Line Research

Mon, 28 Sep 2026 08:00:00 -0400

- Expanded laboratory capabilities support deeper mechanism-of-action research for stenoparib

- New proteomics and cell line capabilities will broaden Allarity’s research capabilities to enable external partnerships

TARPON SPRINGS, Fla., September 28, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor—
today announced that it has expanded the capabilities of its in-house medical laboratory to include proteomics and cell line research.

The new capabilities build on the laboratory’s existing transcriptomics research and CLIA clinical testing services and are

Allarity Therapeutics Expands Laboratory Capabilities to Include Proteomics and Cell Line Research

Mon, 28 Sep 2026 08:00:00 -0400

The new capabilities build on the laboratory’s existing transcriptomics research and CLIA clinical testing services and are

Allarity Therapeutics Expands Laboratory Capabilities to Include Proteomics and Cell Line Research

Mon, 28 Sep 2026 08:00:00 -0400

The new capabilities build on the laboratory’s existing transcriptomics research and CLIA clinical

Allarity Therapeutics Expands Laboratory Capabilities to Include Proteomics and Cell Line Research

Mon, 28 Sep 2026 08:00:00 -0400

The new capabilities build on the laboratory’s existing transcriptomics research and CLIA clinical

Form 8-K Allarity Therapeutics, For: Sep 15

Wed, 16 Sep 2026 08:00:00 -0400

si-local-file:///var/storage/secattach/20260916/27067673.html

Allarity wins Japanese patent for stenoparib diagnostic tool

Tue, 15 Sep 2026 08:03:14 -0400

Allarity Therapeutics, Inc. (NASDAQ: ALLR) announced that Japan's Patent Office has granted a patent covering the company's stenoparib-specific Drug Response Predictor (DRP®) companion diagnostic, according to a press release dated September 15, 2026.

The patent, designated Japanese Patent No. 7917283, provides protection in Japan through 2039. It covers methods for predicting clinical benefit from stenoparib based on gene-expression profiles from tumor samples, as well as methods for selecting patients likely to benefit from stenoparib treatment using the DRP® test.

Thomas Jensen, Chief Executive Officer of Allarity Therapeutics, said: "Japan is one of the world's largest pharmaceutical markets and is also the home

Allarity Therapeutics Granted Japanese Patent for Stenoparib DRP® Companion Diagnostic, Further Strengthening Stenoparib Development

Tue, 15 Sep 2026 08:00:00 -0400

TARPON SPRINGS, Fla., September 15, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor—today announced that the Japan Patent Office (JPO) has granted a key patent covering Allarity’s proprietary stenoparib-specific Drug Response Predictor (DRP®) companion diagnostic. The newly granted patent, Japanese Patent No. 7917283, provides protection in Japan into 2039.

Thomas Jensen, Chief Executive Officer of Allarity Therapeutics, said: “Japan is one of the world’s largest pharmaceutical markets and is also the home of Eisai,

Allarity Therapeutics Granted Japanese Patent for Stenoparib DRP® Companion Diagnostic, Further Strengthening Stenoparib Development

Tue, 15 Sep 2026 08:00:00 -0400

Thomas Jensen, Chief Executive Officer of Allarity Therapeutics, said: “Japan is one of the world’s largest pharmaceutical markets and is also the home of Eisai,

Form 8-K Allarity Therapeutics, For: Sep 11

Mon, 14 Sep 2026 12:14:00 -0400

si-local-file:///var/storage/secattach/20260914/27057315.html

Allarity Therapeutics files SPAC registration for $100M IPO

Fri, 11 Sep 2026 08:01:36 -0400

Allarity Therapeutics, Inc. (NASDAQ: ALLR) has announced that Allarity Acquisition Corp., a newly formed special purpose acquisition company (SPAC), has filed a Registration Statement on Form S-1 with the U.S. Securities and Exchange Commission for a proposed initial public offering.

The proposed offering has a base size of $100 million, which could reach $115 million if underwriters exercise their over-allotment option in full. ALLR Sponsor LLC, a wholly-owned subsidiary of Allarity, is the sponsor of Allarity Acquisition Corp. and is expected to own approximately 25% of the SPAC's issued and outstanding ordinary shares following the offering's completion.

Allarity Acquisition Corp. has applied

Allarity Therapeutics files SPAC registration for $100M IPO

Fri, 11 Sep 2026 08:01:36 -0400

Allarity Acquisition Corp. has applied

Allarity Therapeutics files SPAC registration for $100M IPO

Fri, 11 Sep 2026 08:01:36 -0400

Allarity Acquisition Corp. has applied

Allarity Therapeutics Announces Strategic Capital Allocation for Filing of SPAC Registration Statement

Fri, 11 Sep 2026 08:00:00 -0400

TARPON SPRINGS, Fla., September 11, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated dual PARP/Wnt pathway inhibitor using its proprietary DRP® technology, announced that Allarity Acquisition Corp., a newly formed special purpose acquisition company (SPAC), has publicly filed a Registration Statement on Form S-1 (the “Registration Statement”) with the U.S. Securities and Exchange Commission (“SEC”) relating to a proposed initial public offering of its units.

The proposed initial public offering is expected to have a base offering size of $100 million, or $115 million if

Allarity Therapeutics Announces Strategic Capital Allocation for Filing of SPAC Registration Statement

Fri, 11 Sep 2026 08:00:00 -0400

The proposed initial public offering is expected to have a base offering size of $100 million, or $115 million if

Form 8-K Allarity Therapeutics, For: Aug 14

Fri, 14 Aug 2026 16:39:00 -0400

si-local-file:///var/storage/secattach/20260814/26931791.html

Form 8-K Allarity Therapeutics, For: Aug 14

Fri, 14 Aug 2026 16:39:00 -0400

si-local-file:///var/storage/secattach/20260814/26931791.html

Form 10-Q Allarity Therapeutics, For: Jun 30

Fri, 14 Aug 2026 08:02:00 -0400

si-local-file:///var/storage/secattach/20260814/26924867.html

Form 10-Q Allarity Therapeutics, For: Jun 30

Fri, 14 Aug 2026 08:02:00 -0400

si-local-file:///var/storage/secattach/20260814/26924867.html